Top Story

FDA accepts alirocumab for priority review

January 26, 2015

Sanofi and Regeneron announced that the FDA has accepted the companies’ Biologics License Application for the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab for priority review.

According to a press release, under the Prescription Drug User Fee Act, the goal for a priority review is 6 months, and the agency has a target action date of July 24, 2015.

In the Journals

Majority of PCPs assigned high value to medical imaging

January 26, 2015
The majority of primary care physicians considered access to medical imaging to be essential to patient care, indicating that it aided in establishing earlier and more…
Martin B. Leon, MD 5 Questions with Dr. Bhatt

A Conversation with Martin B. Leon, MD

Cardiology Today's Intervention, January/February 2015
For this issue, Dr. Bhatt talks with Martin B. Leon, MD, professor of medicine at Columbia University Medical Center, director of the Center for Interventional Vascular…
Cross-Pollination: The Catalytic Impact of CTO Interventions CTO Corner

Cross-Pollination: The Catalytic Impact of CTO Interventions

Cardiology Today's Intervention, January/February 2015
Emmanouil S. Brilakis, MD, PhD
Cross-pollination is the process by which pollen is transferred from the anther, or male part, of one plant to the stigma, or female part, of another plant, thereby…
John P. Reilly, MD, FACC, FSCAI Feature

The Challenge of Submassive Pulmonary Embolism

Cardiology Today's Intervention, January/February 2015
With a lack of a large body of randomized clinical trial evidence on the use of catheter-based treatments in patients with pulmonary embolism, physicians face challenges…
More News Headlines »
CME
Individualizing T2DM Treatment: Determining Optimal Pathways That Lead to Achieving Target Goals

Individualizing T2DM Treatment: Determining Optimal Pathways That Lead to Achieving Target Goals

This activity is supported by educational grants from Lilly USA, LLC and Novo Nordisk.

The prevalence of type 2 diabetes mellitus has escalated in recent years and targeting treatmentcontinues to be a…
More »
Meeting News Coverage Video
thumbnail for video 3945938325001

Kirk N. Garratt, MD: Prolonged DAPT beneficial in patients with paclitaxel-eluting stents

December 16, 2014
CHICAGO — In this video, Kirk N. Garratt, MD, of the Lennox Hill Hospital, New York, outlines results of a study…
More »
CME
HIV-Associated Lipodystrophy and Metabolic Complications: A Multidisciplinary Approach to Diagnosis and Treatment

HIV-Associated Lipodystrophy and Metabolic Complications: A Multidisciplinary Approach to Diagnosis and Treatment

This activity is supported by an educational grant from EMD-Serono.

Clinicians who manage patients with HIV must be aware of how to screen for, diagnose, and treat metabolic abnormalities…
More »
morganatic-roan